In this context, evidences demonstrated that administration of isoflavone-based agents, including Calycosin and Genistein, play dose-dependently anti-tumour roles in breast cancer cells by inhibiting HOTAIR expression and phosphorylation of Akt causing suppression of PI3K/AkT signalling pathway and consequently defect of apoptosis inhibitors, BCL-2 family and casepases. This evidence concerns the gene AKT1 and breast carcinoma.